首页> 外国专利> METHOD FOR MANUFACTURING A PHARMACEUTICAL COMPOSITION IN THE FORM OF EXTENDED-RELEASE TABLETS CONTAINING PIRFENIDONE AND USE THEREOF IN THE REGRESSION OF CHRONIC RENAL INSUFFICIENCY, BREAST CAPSULAR CONTRACTURE AND HEPATIC FIBROSIS IN HUMANS

METHOD FOR MANUFACTURING A PHARMACEUTICAL COMPOSITION IN THE FORM OF EXTENDED-RELEASE TABLETS CONTAINING PIRFENIDONE AND USE THEREOF IN THE REGRESSION OF CHRONIC RENAL INSUFFICIENCY, BREAST CAPSULAR CONTRACTURE AND HEPATIC FIBROSIS IN HUMANS

机译:制造包含吡非尼酮的可延缓释放片剂形式的药物组合物的方法,及其在人类慢性肾功能不全,乳房包膜狭窄和肝纤维化中的应用

摘要

The instant invention relates to a process for the preparation of a pharmaceutical composition in sustained-release tablet form comprising from 600 milligrams to 2400 milligrams of Pirfenidone (PFD), in such a way that the drug is bioavailable during an extended period of time of 12 hours from its administration. In this way, the anti-fibrotic and anti-inflammatory action of the drug Pirfenidone is optimized. Moreover, the instant invention offers advantages and a higher therapeutic efficacy compared to other pharmaceutical forms of Pirfenidone for oral administration and its therapeutic application in the regression of chronic renal failure secondary to primary glomerulosclerosis; it shows a better activity with regard to the reduction and/or regression of deleterious effects in breast capsular contracture observed after the surgical implantation of breast implants in humans and has an important anti-TNF-± and anti-TGF-²1 action for the treatment of hepatic fibrosis.
机译:本发明涉及一种制备缓释片剂形式的药物组合物的方法,该药物组合物包含600毫克至2400毫克的吡非尼酮(PFD),使得该药物在延长的12小时内可被生物利用。从管理开始数小时。这样,药物吡非尼酮的抗纤维化和抗炎作用得以优化。此外,与吡非尼酮的其他药物形式相比,本发明具有口服给药的优点和更高的治疗功效,并且其在退行于原发性肾小球硬化的慢性肾衰竭中的治疗应用中。在人类植入乳房植入物后观察到的减少和/或消退乳房荚膜挛缩的有害作用方面,它具有更好的活性,并且对治疗具有重要的抗TNF-±和抗TGF-²1作用肝纤维化。

著录项

相似文献

  • 专利
  • 外文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号